Rethinking brain health

We are on a mission to change the way the world thinks about brain health.

Oxford Brain Diagnostics is committed to analysing the cellular structure of the brain in a way no one else can, to support drug development and aid clinicians around the world in their fight to defeat Alzheimer’s and other neurodegenerative diseases.

The Challenge

Our novel technology assesses brain health based on changes in the cellular structure.

Our pioneering approach, and novel measures unlock unique insights that enable us to predict, detect, quantify, track and differentiate neurodegenerative diseases.

This gives us the potential to revolutionise how people think about brain health and disease management.

Our solution

Supporting more efficient drug development and personalised patient care.

Previously inaccessible insights unlocked by our proprietary technology will support more targeted, efficient drug development.

Our Science

Our products

Pharma/Biotech

  • Measures you can trust
  • Get more from your MRI
  • Run targeted, more efficient clinical trials
  • Efficient use of technology across multiple conditions

Our products

Clinical

  • Better patient care
  • Improving certainty in diagnosis
  • Differential diagnosis for Dementia
  • Accurately tracking decline
  • Proactive brain health

Clinical Information

Latest news

OBD Guest Speaker series Professor Takeshi Iwatsubo
Video
31 August 2022

It was a pleasure to welcome Professor Takeshi Iwatsubo to our guest speaker series. Takeshi Iwatsubo is a professor of neuropathology at the School of Medicine, University of Tokyo. Originally trained as a neurologist and neuropathologist, he has contributed to the studies of human neurodegenerative disorders, especially Alzheimer's (AD) and Parkinson's disease, using multidisciplinary approaches. Professor Iwatsubo provides a comprehensive review of the J-ADNI project and the insights to date. He further expanded on his laboratory's role to build a Japanese Trial Ready Cohort for preclinical/prodomal AD (J-TRAC). Progress is being made already with this approach, starting enrollment with the AHEAD, Trailblazer ALZ3 and other preclinical AD trials.

AAIC 2022 San Diego
News Release
21 July 2022

Dr Steven Chance and Omar Ehsan will be attending Alzheimer's Association International Conference 2022 in San Diego. We will present two posters. Come along and chat to us. We look forward to connecting with the AD global community and listening to all the wonderful scientific research and updates on clinicaltrials. We have plenty to share, say and play our part in defeating this terrible condition. Our two posters: 03 August (P4-199) - 'Regional pattern of cortical microstructural alterations along the AD continuum and association with plasma neurofilament light' 02 August (P3-189) - 'Ante mortem imaging of cortical microstructure relates to post mortem locus coeruleus hypopigmentation in autopsy-confirmed Alzheimer's disease'

OBD Guest Speaker series Dr Jeffrey L Cummings
Video
04 July 2022

It was a pleasure to host Dr Jeffrey Cummings in our guest speaker series. He provided an extensive review of the Alzheimer's drug development pipeline and identified a growing mix in that pipeline as other target mechanisms are being explored. During the session he reiterated the importance of having biomarkers in AD clincial trials as critical for future trials.

OBD Guest Speaker series Dr Liana Apostolova
Video
27 June 2022

Dr Apostolova, is an IU Distinguished Professor and the Barbara and Peer Baekgaard Professor in Alzheimer's Disease Research and Professor in Neurology, Radiology, Medical and Molecular Genetics. In this session, she provides a more detailed perspective on the dynamics surrounding the use of Aducanumab and how best to track the potential side effects of that use (ARIA) with effective tools like MRI monitoring.